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Abstract
4,4′-Methylene diphenyl diisocyanate (herein 4,4′-MDI) is used in the production of polyurethane 
foams, elastomers, coatings, adhesives and the like for a wide range of commercial products. 
Occupational exposure to MDI levels above current airborne exposure limits can elicit immune 
mediated hypersensitivity reactions such as occupational asthma in sensitive individuals. To 
accurately determine exposure, there has been increasing interest in developing analytical methods 
to measure internal biomarkers of exposure to MDI. Previous investigators have reported 
methodologies for measuring MDI diamine metabolites and MDI-Lysine (4,4′-MDI-Lys) adducts. 
The purpose of this study was to develop and validate an ultra performance liquid chromatography 
isotope dilution tandem mass spectrometry (UPLC-ID/MS/MS) quantitation method via a 
signature peptide approach to enable biomonitoring of 4,4′-MDI adducted to human serum 
albumin (HSA) in plasma. A murine, anti-4,4′-MDI monoclonal IgM antibody was bound to 
magnetic beads and utilized for enrichment of the MDI adducted HSA. Following enrichment, 
trypsin digestion was performed to generate the expected 414 site (primary site of adduction) 4,4′-
MDI-adducted HSA signature peptide that was quantified by UPLC-ID/MS/MS. An Agilent 6530 
UPLC/quadrupole time of flight MS (QTOF) system was utilized for intact adducted protein 
analysis and an Agilent 6490 UPLC/MS/MS system operated in multiple reaction monitoring 
(MRM) mode was utilized for quantification of the adducted signature peptide biomarker both for 
in chemico and worker serum samples. Worker serum samples were initially screened utilizing the 
previously developed 4,4′-MDI-Lys amino acid method and results showed that 12 samples were 
identified as quantifiable for 4,4′-MDI-Lys adducts. The signature peptide adduct approach was 
applied to the 12 worker samples identified as quantifiable for 4,4′-MDI-Lys adducts. Results 
indicated no positive results were obtained above the quantification limit by the signature peptide 
approach. If the 414 site of lysine adduction accounted for 100% of the 4,4′-MDI adductions in the 
signature peptide adduct approach, the three highest quantifiable samples by the 4,4′-MDI-Lys 
method should have at least been detectable by the signature peptide method. Results show that 
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although the 4,4′-MDI signature peptide approach is more selective, it is 18 times less sensitive 
than the 4,4′-MDI-Lys method, thus limiting the ability to detect adduct levels relative to the 4,4′-
MDI-Lys amino acid method.
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1. Introduction
In commerce, a majority of methylene diphenyl diisocyanate (MDI) is sold as “monomeric 
MDI” (typically containing greater than 95% of the 4,4′-MDI isomer) or “polymeric MDI” 
(pMDI). These diisocyanates are important industrial chemicals used in a variety of 
commercial and consumer applications such as thermoplastic polyurethanes, fibers, sealants, 
coatings, automotive bumpers, fenders and fascia, integral-skin plastics, tires and wheels, 
industrial wheels, shoe soles, recreational goods, and mechanical goods.
Occupational exposure to MDI levels above current airborne exposure limits can elicit 
immune mediated hypersensitivity reactions such as occupational asthma in sensitive 
individuals [1]. Hence, current industrial hygiene practices such as the utilization of personal 
protective equipment are designed to limit exposure below established exposure limits 
obviating potential health effects [1]. An important tool in the determination of worker 
exposure is the measurement of airborne MDI in the workplace. However, the external 
exposure measurements of MDI may not be representative of actual internal body burden 
levels, thus there has been increasing interest in developing analytical methods to measure 
internal biomarkers of exposure for MDI.
An understanding of the major metabolic pathways for MDI provides insight into potential 
biomarkers to measure internal exposure to MDI. Gledhill and coworkers [2] demonstrated 
that the major metabolites after inhalation exposure to 14C-MDI were the mono- and di-
acetylated compounds with the methylene bridge oxidized to various states. This supports 
the most common method, measuring liberated hydrolysis products following acid digestion 
of protein conjugates in biological fluids. Some researchers have suggested that methylene 
diphenyl diamine (MDA) can be formed after exposure to MDI, and that the hydrolysis 
method could confound biomonitoring efforts for MDI as the metabolic products are the 
same whether there is MDI or MDA exposure [3–11]. Recent work by Wisnewski and 
coworkers [12] addresses alternative mechanisms associated with toluene diamine (TDI) 
metabolism, which is applicable to MDI. This work provides evidence that accounts for the 
formation of metabolites observed in the Gledhill et al. [2] study without the necessity of 
invoking the presence of free MDA as an intermediate. Most importantly, the hydrolysis 
method while tested [13] has not been fully validated, as incomplete release of MDA from 
protein conjugation may underestimate MDI exposure levels.
Beyond hydrolysis measurements, some investigators have moved to measuring MDI 
specifically adducted to circulating proteins. Groups have investigated 4,4′-MDI-
hemoglobin adducts at the N-terminal valine [14]. Gries and Leng validated a method that 
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measured hydantoin adducts levels in plasma which formed following acid treatment of 4,4′-
MDI conjugated to the N-terminal amino acid [15]. Sufficient sensitivity was achieved to 
quantify the possible adduct levels, however poor analyte recoveries were observed 
following 2 M HCl hydrolysis (2 h at 80 °C) and solid phase extraction (SPE) cleanup of the 
biological samples (or spiked matrix samples). These low recoveries were likely a function 
of analyte degradation during the hydrolysis process or loss of the analyte during the SPE 
cleanup process. Additional work would be required to establish if technical modifications 
might make this methodology useful for 4,4′-MDI-hemoglobin adducts, and if this 
methodology would be sensitive enough to inform worker exposures.
More recently, Kumar and coworkers have identified and quantified 4,4′-MDI-Lys amino 
acid adducts in rats and humans [16–18]. Both 4,4′-MDI-Lys and acetylated 4,4′-MDI-Lys 
(AcMDI-Lys) adduct levels were quantified from human serum following human serum 
albumin (HSA) purification, pronase digestion, and SPE cleanup. However, due to the lack 
of a peptide sequence the amino acid adduct method does not provide HSA protein 
biomarker confirmation. As a consequence, the 4,4′-MDI-Lys and AcMDI-Lys quantitative 
results rely on the purity of the HSA fraction collected. Due to the non-specificity of the 
albumin purification method utilized, an overestimation in MDI albumin adducts levels 
could result due to adduct contributions from other proteins.
However, Wisnewski and coworkers [19] have identified 12 MDI lysine peptide conjugation 
sites with IgG on human albumin which when utilized as a biomarker of exposure could 
increase specificity by not relying on the purity of the HSA fraction. Recent advances in the 
development of diisocyanate-specific monoclonal antibodies have provided a new approach 
to detecting diisocyanate adducts [20–22]. The advantages of measuring protein adduct 
biomarkers are specificity for at least one diisocyanate adduct, a slow turnover (i.e., half-life 
of HSA is approximately 20 days) and therefore represents a viable potential tool for 
monitoring long-term exposure [23,24].
Therefore, to overcome the current selectivity limitations associated with 4,4′-MDI-Lys 
amino acid biomarker quantification methods described above, we aimed to develop and 
validate a highly specific HSA signature peptide approach [25–28] to identify and quantify 
4,4′-MDI HSA protein adducts formed in chemico and sera from a human cohort population. 
We employ a highly specific IgM monoclonal antibody to capture the 4,4′-MDI adducted 
HSA proteins from sera, digest the captured adducted albumin with trypsin to produce the 
4,4′-MDI adducted signature peptide biomarker and analyze with ultra performance liquid 
chromatography isotope dilution tandem mass spectrometry (UPLC-ID/MS/MS).
2. Methods
2.1. In chemico
2.1.1. Conjugation of 4,4′-MDI to HSA—To 1 mg/mL solutions of HSA, 0 mM, 0.01 
mM, 0.1 mM and 1 mM of 4,4′-MDI were added and incubated with rotation at 37 °C for 2 
h. Following incubation, each reaction was quenched with the addition of 0.5% acetic acid 
and vortex-mixed. Excess 4,4′-MDI was removed by centrifugation (10 min at 15,000 × g). 
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Samples were transferred to autosampler vials for intact protein analysis via the Agilent 
6530 UPLC/QTOF (Agilent, Santa Clara, CA) system as described below.
2.1.2. HSA-4,4′-MDI adduct stability—To determine stability of the 1 mM 4,4′-MDI 
adducted HSA, aliquots were stored at room temperature and −80 °C. Each sample was 
analyzed on days 1, 4 and 8 after initial analysis of freshly prepared adducted HSA by 
UPLC/QTOF as described below to determine stability.
2.1.3. LC/MS–MS conditions for intact HSA-adduct analysis—An Agilent 1290 
UPLC system (Agilent, Santa Clara, CA) was utilized for intact adducted protein analysis. 
The analytical column utilized was a Zorbax rapid resolution 300SB-C18 (part number 
863974-302, Agilent) 3 × 150 mm-i.d. (3.5 μm particle size). The aqueous mobile phase (A) 
was 0.1% acetic acid/water, and the organic phase (B) was 0.1% acetic acid/acetonitrile 
(ACN). After injection of 2 μL sample onto the column the sample was eluted at 400 μL/min 
from the column using a solvent gradient that initially consisted of 99% A and 1% B for 1 
min, and then a 5.5% increase in B for the next 13.5 min to a final concentration of 75% B. 
The column eluent was introduced into an Agilent 6530 QTOF (Agilent) mass spectrometer 
with an electrospray ionization interface. The instrument, operated in full scan mode, was 
utilized for intact adducted protein analysis. The instrument was operated in the positive ion 
mode with a survey scan range from 800 to 3000 Da. Instrument parameters were as 
follows: gas temperature 350 °C, gas flow 10 L/min, nebulizer 60 psi, fragmentation voltage 
was 250 V and the capillary voltage was 3500 V. Instrument control and data processing 
were performed with the Mass Hunter software version for B.02.01 data acquisition and B.
05.00 for qualitative analysis.
2.1.4. HSA adduct digestion—To determine the extent of adduction, the 1 mM 4,4′-
MDI adducted HSA was digested with trypsin. Specifically, 5 μL of the 1 mM 4,4′-MDI 
adducted HSA and 45 μL of human plasma (sodium heparin, Bioreclamation, West-bury, 
NY) were transferred to a microfuge tube. Two hundred and fifty μL of 50 mM ammonium 
bicarbonate was added to adjust the pH to 7.8. Fifty μL of 0.1% Rapigest SF (Waters, 
Milford, MA) was added to the same microfuge tube and incubated for 5 min at 100 °C to 
solubilize the adducted protein and make it more susceptible to enzymatic cleavage without 
inhibiting enzyme activity. The sample was allowed to cool to room temperature and 20 μg 
(~45 μL) of modified trypsin (Promega, Madison, WI, V5113) was added and incubated 
overnight at 37 °C to digest the adducted HSA into predictable trypsin cleaved peptides. The 
sample was subsequently removed from the incubator and allowed to cool to room 
temperature. One hundred μL of 175 mM HCl was added to adjust the pH to approximately 
2 and incubated for an additional 30 min at 37 °C to break down the Rapigest surfactant into 
small molecules. The sample was removed from the incubator and allowed to cool to room 
temperature. Fifty five μL of a 1 μg/mL 13C 15N internal standard (ISTD, 
KVPQVSTPTLV(+6)EVSR) solution was added to the digest. Final volume was 
approximately 550 μL. The sample was transferred to an autosampler vial for UPLC-
ID/MS/MS analysis.
The same process described above was followed for control HSA. Ten mL of mixed gender 
unfiltered human plasma (sodium heparin, Bioreclamation) aliquoted into 1 mL increments 
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and stored at −80 °C. After the human plasma was thawed to room temperature, human 
plasma was digested with trypsin as described above.
2.1.5. MDA adducted amino acid/peptides syntheses—Adduction of lysine with 
4,4′-MDI, results in the nucleophilic addition of an isocyanate group (N=C=O) that 
produces a methylene dianaline (MDA) urea adduct on the lysine amino acid side chain. To 
determine the primary site of adduction, identified peptides with a MDA urea adduct were 
synthesized (New England Peptide, Gardner, MA) to lysine positioned in the 234, 413 and 
or 414 on various HSA tryptic peptides to include one missed cleavage at the 413 and 414 
sites of adduction. The unlabeled synthesized MDA adducted lysine amino acid and peptides 
are listed in Table 1 and the peptide adduct synthesis is shown in Fig. 1. Fig. 1 illustrates 
that following hydrogenation and de-protection during the synthesis process to produce an 
intermediate, MDA is introduced in excess and the final cleavage product, the peptide with 
an MDA adduct, is formed (resulting in a change in molecular weight of 224 Da).
2.1.6. Monoclonal 4,4′-MDI IgM antibody production—The monoclonal antibody 
(mAb) 15D-1C4-1C3, an anti-aromatic and aliphatic diisocyanate IgM producing hybridoma 
cell line [20] was grown in complete DMEM over a period of three weeks. Culture 
supernatant was collected following the splitting of confluent cell lines. Approximately 2 L 
of hybridoma culture supernatant was collected, centrifuged, and filter sterilized. Protease 
activity was inhibited by the addition of Roche protease inhibitor per 500 mL culture 
supernatant. The IgM mAb 15D-1C4-1C3 was precipitated and concentrated using a 
saturated ammonium sulphate precipitation method. The mAb pellet was resuspended in 
NaHCO3 buffer, dialyzed against NaHCO3 buffer, and then lyophilized. The lyophilized 
mAb was reconstituted in Dulbecco's Phosphate-Buffered Saline (DPBS, Gibco, Life 
Technologies, Grand Island, NY) at 1 mg/mL and stored at −20 °C until use.
2.1.7. Immunoaffinity purification of MDI conjugated proteins—One mL of 
secondary coated IgM Dynabeads (110.39D Invitrogen, Carlsbad, CA) was washed twice 
with DPBS. To the washed secondary coated IgM Dynabeads, 60 μL primary 15D-1C4-1C3 
IgM mAb murine monoclonal antibody was added along with 440 μL DPBS and allowed to 
incubated with rotation at room temperature for 2 h. After the 2 h binding period, the 
supernatant was removed and antibody-bead complex was washed twice with DPBS and 
stored in 1 mL DPBS solution at 4 °C until needed.
Five μL of the 1 mM 4,4′-MDI adducted human albumin was diluted 1:10, 1:100 and 1:1000 
in human plasma. Dilutions were added to 200 μL of the above antibody bead complex and 
incubated at 37 °C with rotation overnight. After incubation, the supernatant was removed 
from the microfuge tubes and the remaining antigen–antibody bead bound complex was 
washed twice with 1 mL DPBS. The beads were resuspended in 50 μL of 0.1% Rapigest 
(Waters, Milford, MA) and 250 μL of 50 mM ammonium bicarbonate, heated at 100 °C for 
5 min, allowed to cool to room temperature, and then 20 μg (~45 μL) of sequencing grade 
modified trypsin was added (Promega, V5113). Samples were briefly vortex-mixed and 
subsequently incubated on a water bath at 37 °C overnight. After tryptic digestion, 100 μL 
of 175 mM HCl was added to adjust the pH to approximately 2 and an additional incubation 
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at 37 °C for 30 min to break down the acid labile surfactant into small molecules was 
performed. The total final digest volume was ~550 μL.
2.1.8. LC/MS–MS conditions for quantification of the HSA adducted peptide 
biomarker—MDI-peptide adduct standards were prepared in 50:50 water:acetonitrile with 
0.1% formic acid from 1 ng/mL to 200 ng/mL. Matrix standards, with trypsin digested 
albumin from human serum (A8763, Sigma, St. Louis, MO) as the matrix, were prepared 
over the same range of concentrations. The analytical column utilized was a 300 SB RRHD 
(Agilent, part number 857750-902) 2.1 × 50-mm-i.d. reversed-phase C18 (1.8 μm particle 
size). The aqueous mobile phase (A) consisted of Milli-Q (18 MΩ) water with 0.1% formic 
acid, while the organic phase (B) was ACN with 0.1% formic acid. The autosampler was 
programmed to deliver a 10 μL injection. A gradient profile was utilized at a flow rate of 
500 μL/min. The mobile phase was held for 1 min at of 95% A and 5% B and then B was 
increased at 19% per minute for the next 3.5 min to a final concentration of 28% A and 72% 
B, respectively.
An Agilent 6490 UPLC–MS/MS (Agilent) system operated in positive ESI multiple reaction 
monitoring (MRM) mode was utilized for quantification of the adducted peptide biomarker. 
The UPLC column eluent was introduced into a 6490 Agilent triple-quadrupole mass 
spectrometer with a jet spray interface. For multiple reaction monitoring, the instrument was 
operated in the positive ion mode with mass-to-charge (m/z) MRM transition pairs listed in 
Table 2. The collision energy for each transition was optimized. Instrument parameters were 
as follows: gas temperature 350 °C, gas flow 11 L/min, nebulizer 30 psi, sheath gas heater 
400 °C, sheath gas flow 12, and the capillary voltage was 4000 V. Dwell time was 100 ms 
per transition and the fragmentation voltage was set to 380 V. Instrument control and data 
processing were performed with the Mass Hunter software version for B.04.01 data 
acquisition and version B.05.00 for both qualitative and quantitative analysis.
2.2. In vivo
2.2.1. Human sera screened utilizing 4,4′-MDI-Lys amino acid methodology—
De-identified sera samples, approved by The Dow Chemical Company human subject 
review board, from human workers with known 4,4′-MDI exposures were obtained from the 
laboratory of Dr. Jean-Luc Malo at the Hôpital du Sacré-Coeur de Montréal. Demographic 
and classification information for sera samples is provided in Tables S1–S4. These samples 
were collected from workers undergoing specific inhalation challenge (SIC) in order to 
establish the diagnosis of diisocyanate related asthma as part of the worker compensation 
program. Workers were exposed to MDI in an enclosed-circuit inhalation apparatus, which 
maintained a constant concentration of diisocyanates below 20 ppb. The standardized 
protocol used was exposure of subjects for 1–4 min on the first day, 5–30 min on the second 
day, and 2 h on the third day, unless a decrease in FEV1 of 20% or more was observed 
immediately or 10 min after stopping exposure. The sensitivity and specificity of 4,4′-MDI 
HSA adduct determinations via the peptide method and to that of the previously published 
4,4′-MDI-Lys method [17] were compared. Briefly, for the 4,4′-MDI-Lys method, 500 μL of 
human sera albumin (HSA) was purified through a HiTrap Blue column. The purified eluent 
containing the adducted HSA was subsequently centrifuged (15 min, 4000 × g) though a 30 
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kDa molecular weight cutoff filter. Two water washes were performed by centrifugation of 
the 30 kDa molecular weight cutoff filter. The concentration of the purified HSA in the 
retentate was determined by the bicinchoninic acid assay protein assay and 10 mg of 
purified albumin/mL was Pronase E digested for approximately 12 h at 37 °C. Five ng/mL 
of 13C 15N K ISTD (underlined K indicates MDI adducted lysine) was added prior to 
digestion. After digestion, samples were cleaned up utilizing SPE columns (Phenomenex, 
Strata-X 33u Polymeric Reversed Phase, 200 mg/3 mL, part number 8B-S100-FBJ). The 
column was activated with 3 mL of methanol and then equilibrated with distilled de-ionized 
water. The sample was applied to the SPE column and then washed with 3 mL of distilled 
de-ionized water, 3 mL of 90:10 distilled de-ionized water:methanol and 3 mL of 
80:distilled de-ionized water–methanol. The sample was then eluted with 6 mL of 20:80 
distilled de-ionized water: methanol. The SPE eluent was evaporated to dryness and 
reconstituted in 100 μL of 50 mM ammonium bicarbonate. Samples were vortex-mixed prior 
to analysis on an AB/Sciex 4000 QTRAP.
Supplementary Tables S1–S4 related to this article can be found, in the online version, at 
doi:10.1016/j.toxrep.2014.09.009.
2.2.2. Human sera screened utilizing the 4,4′-MDI signature peptide adduct 
methodology—Sera samples that were previously identified as containing 4,4′-MDI-Lys 
adducts [17] were subsequently screened with the modified signature peptide adduct 
method. To obtain definitive analyses of 4,4′-MDI signature peptide adducts, a 0.5 mL 
aliquot of each positive human sera was allowed to bind to the primary murine anti-
diisocyanate IgM antibodies, trypsin digested and analyzed as described previously.
3. Results and discussion
3.1. In chemico
3.1.1. Exposure of 4,4′-MDI to HSA—Fig. 2 contains deconvoluted full scan mass 
spectra taken in positive ion electrospray ionization mode of (A) HSA; (B) 0.01 mM 4,4′-
MDI adducted HSA; (C) 0.1 mM 4,4′-MDI adducted HSA; and (D) 1 mM 4,4′-MDI 
adducted HSA. Fig. 2A demonstrated two major isoforms of HSA at [M+H]+ of 66,440 Da 
and 66,560 Da consistent with that previously reported [29–31]. When 0.01 mM of 4,4′-
MDI was incubated with the HSA (Fig. 2B) adduction appeared to be evident and produced 
a mass difference of 224 indicative of an MDA adduction. At the 0.1 mM and the 1 mM 
4,4′-MDI concentrations (Fig. 2C and D), MDA adduction were apparent on both isoforms, 
as well as multiple MDI additions to a single HSA molecule, which may represent adduction 
to multiple amino acid residues and/or polymerization onto a single nucleophilic site. Also 
evident were the decreased signal intensities of both isoforms and increased signal 
intensities at m/z ratios at the respective MDA adductions.
3.1.2. HSA adduct stability—MDI-HSA adducts were analyzed on days 0, 1, 4 and 8 
after preparation. Results demonstrated that the samples were stable over the entire 8 days 
when stored at either −80 °C or room temperature conditions (data not shown).
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3.1.3. HSA adduct peptide identification—Targeted peptides from the 1 mM 4,4′-
MDI adducted HSA trypsin digest were identified via data-dependent UPLC–MS/MS 
acquisition and subsequent analysis. Results in Fig. 3A show the adducted peptide 
KVPQVSTPTLVEVSR. A triply charged precursor (M+3H)3+ ion dominant at a m/z ratio 
of 622.0 of the MDI peptide adduct was observed. When the precursor ion was subjected to 
MS/MS fragmentation, the fragmentation pattern (Fig. 3B) confirmed the amino acid 
sequence of the adducted peptide. Precursor ions and fragmentation patterns were also 
confirmed for K, YTK, KQTALAELVK and AFKAWAVAR from MDI adducted HSA. A 
precursor (M+3H)3+ was identified for adducted peptides YTKKVPQVSTPTLVEVSR and 
YTKKVPQVSTPTLVEVSR, however ion abundance was insufficient for MS/MS 
fragmentation confirmation.
For confirmation, tandem mass spectrometry analysis was performed on the HSA trypsin 
digests. Full scan and fragmentation data files utilized the Mascot database search engine 
(Matrix Science, Boston, MA) which employs probability base scoring, significance level, 
mass tolerances and sequence query scoring [32] to confirm identification of the MDI-
derived trypsin digested HSA peptides from the non-redundant database of the National 
Center for Biotechnology Information (NCBI) for peptide and protein adduct identification. 
Results confirmed identification for three 4,4′-MDI HSA trypsin derived peptide adducts: 
AFKAWAVAR, KQTALAELVK and KVPQVSTPTLVEVSR (all peptides have one 
missed cleavage). The missed cleavage in each peptide is not unexpected due to the large 
4,4′-MDI substituent present and likely hindering trypsin's ability to cleave at these sites. 
The identified MDI adducts with HSA were consistent with those reported by Wisnewski's 
research group [19].
3.1.4. Primary site of adduction—For external calibration purposes, matrix standards 
(trypsin digested HSA) were prepared from 1 ng/mL to 200 ng/mL. Quantification of the 1 
mM 4,4′-MDI adducted HSA trypsin digest was performed. No quantifiable amounts 
resulted for K and YTK. Results showed that the KVPQVSTPTLVEVSR peptide had a 
concentration of 276 ng/mL. This resulted in a 10.3% recovery of the adducted peptide 
when 0.1 mg of HSA was digested. Recovery was 1.2% for the AFKAWAVAR peptide. 
This demonstrates that of the peptides monitored, the primary site of adduction appears to be 
the 414 site, KVPQVSTPTLVEVSR.
3.1.5. Sensitivity comparison with and without immunoaffinity purification—
Five μL aliquots of the 1 mM 4,4′-MDI adducted human albumin (1 mg/mL) were diluted 
1:10, 1:100 and 1:1000 in human plasma. Trypsin digestion was performed on samples with 
and without antibody capture. Results demonstrated in the absence of immunoaffinity 
purification adducted albumin could only be detected at the 1:10 dilution, while adducted 
albumin was non-quantifiable at the 1:1000 dilution. Capture efficiency was 99.5%, 70.8% 
and 69.4% when the 1 mM 4,4′-MDI adducted human albumin was diluted 1:10, 1:100 and 
1:1000 in plasma respectively (n = 1 per protein level).
3.1.6. Suppression effects with peptide adduct methodology—Comparison of 
solvent standards to matrix standards showed that there is approximately a 30% suppression 
effect occurring in the matrix standards. When the internal standard was added at 100 ng/mL 
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the area counts showed an average of 18,040 counts in solvent standards while in matrix 
standards the average internal standard area count was 12,624 demonstrating a suppression 
of 30%. A comparison of the signal-to-noise ratio was also performed of the 100 ng/mL 
matrix standard before and after a 10-fold dilution in solvent (50:50 water:acetonitrile with 
0.1% formic acid). Results demonstrated that the signal-to-noise ratio of the 100 ng/mL 
matrix standard prior to dilution was approximately 114 and after the 10-fold dilution with 
solvent was approximately 29. However, the increased signal-to-noise ratio achieved by 
dilution of the matrix (2.5×) cannot overcome the absolute dilution of the analyte to enhance 
the peptide method detection limit.
3.1.7. Screening of serum samples by the 4,4′-MDI-Lys amino acid 
methodology—Human sera samples from workers with potential MDI exposure were 
purified for HSA, pronase digestion, SPE cleaned up and assayed for 4,4′-MDI-Lys as 
previously described (Kumar et al. [16]). 4,4′-MDI-Lys could be detected in 8 of the 15 
MDI-asthmatic workers, but only 4 of the 15 had quantifiable levels (Supplementary Table 
S1) and maybe attributable to the half-life of albumin from when the date of last exposure 
took place to the time the actual sera samples were collected. 4,4′-MDI-Lys was detectable 
in a proportion of all workers, independent of disease status (Supplementary Tables S1–S4). 
Overall the 4,4′-MDI-Lys method could quantify adduct levels in 12 human sera samples 
from the human cohort above the limit of quantification (LOQ) for the method (Table 33). 
Concentrations of 4,4′-MDI-Lys ranged from 7.55 to 151 fmol adducted albumin/mg of 
albumin with the highest level of adduct observed in a non-exposed control. Sabbioni and 
coworker's [17] construction worker cohort identified 15% of the construction worker 
controls as positive with the 4,4′-MDI-Lys method. In the present human cohort, the 
presence of a high level of 4,4′-MDI-Lys observed in the non-exposed individual may be 
due to either a non-occupational exposure to MDI or lack of recognition of use of a MDI-
containing product.
3.1.8. Screening of positive serum samples with signature peptide adduct 
methodology—The 12 sera positive with quantifiable 4,4′-MDI-Lys adducts were 
subsequently screened by the 4,4′-MDI-signature peptide adduct method as described above. 
No 4,4′-MDI-signature peptide adduct positive results were obtained from the 12 samples 
(LOQ = 13.4 fmol adducted albumin/mg of albumin or matrix LOQ = 134 fmol adducted 
albumin/mg of albumin). If the 414 site accounted for 100% of the adduction, the three 
highest quantifiable samples by the 4,4′-MDI-Lys method should have at least been 
detectable by the signature peptide method. However an additional 5–19 exposure dose 
dependent lysine adduction sites have been demonstrated on HSA [20,22].
4. Conclusions
The MDI adducted HSA is stable at both −80 °C and room temperature over 8 days. Of the 
possible HSA peptide adducts, the 414 adduct (KVPQVSTPTLVEVSR) appears to be a 
primary site of adduction. The peptide adduct method is 18 times less sensitive than the 4,4′-
MDI-Lys method thus, limiting the ability to detect adduct levels relative to 4,4′-MDI-Lys 
method. While the adducted KVPQVSTPTLVEVSR peptide method is more selective and 
potentially the primary site of adduction, the additional 5–19 exposure dose dependent 
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lysine adduction sites have been demonstrated on HSA, all of which would potentially 
contribute non-specifically to the total 4,4′-MDI-Lys measured following pronase digestion. 
Thus, while more specific, the 4,4′-MDI-signature peptide method's sensitivity appears to be 
inadequate for biomonitoring of workers’ exposure to MDI.
Biomonitoring is superior to many other exposure assessment methodologies since it allows 
assessment of the actual exposure on the individual level. While increased selectivity was 
achieved with the signature peptide method, it could not overcome sensitivity limitations 
discussed above. The Sabbioni method [17] appears to have the sensitivity to detect and 
quantify 4,4′-MDI-Lys adducts at the NIOSH and OSHA external occupational exposure 
limit of 0.2 mg/m3.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Fig. 1. 
Synthesis process to adduct MDA to the lysine side chain on a peptide.
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Fig. 2. 
Deconvoluted full scan mass spectra taken in positive ion electrospray ionization mode of 
(A) control HSA; (B) 0.01 mM 4,4′-MDI adducted HSA; (C) 0.1 mM 4,4′-MDI adducted 
HSA; and (D) 1.0 mM 4,4′-MDI adducted HSA. The single asterisk indicates the first 
isomer of HSA while the double asterisk indicates a second isomer. The change in molecular 
weight is 224 Da.
Luna et al. Page 14
Toxicol Rep. Author manuscript; available in PMC 2016 February 10.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Fig. 3. 
Adducted peptide KVPQVSTPTLVEVSR (A) full scan and (B) product ion scan.
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Table 1
4,4′-MDI HSA derived lysine amino acid and peptide adducts. Underlined lysine (K) indicates the site of MDI 
adduction.
HSA site of adduction MDI adducted amino acid or peptide MW (g/mol)
Any, non-specific K 371.11
236 AFKAWAVAR 1242.67
413 YTK 634.22
414 KVPQVSTPTLVEVSR 1862.93
413 KKVPQVSTPTLVEVSR 2255.14
414 KKVPQVSTPTLVEVSR 2255.14
549 KQTALAELVK 1323.66
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Table 2
Multiple reaction monitoring transitions and corresponding collision energies for labeled and unlabeled 
adducted HSA peptides. Underlined lysine (K) indicates the site of MDI adduction.
Adducted peptide Monoisotopic transition pairs Optimized collision energies
Precursor Product
AFKAWAVAR 622.3 (+2) 673.1 16
KQTALAELVK 662.9 (+2) 844.5 16
YTK 635.3 (+1) 371.2 16
KVPQVSTPTLVEVSR 622.0 (+3) 900.5 18
589.3 18
450.8 18
KVPQVSTPTLVEV(+6)SR 624.3 (+3) 906.5 18
595.3 18
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Table 3
Summary demographic and classification information for all sera samples.
Parameter Exposed to 
diisocyanates 
workers with 
diisocyanate related 
asthma n = 15
Exposed to 
diisocyanate workers 
non-asthmatic no 
diisocyante related 
asthma n = 10
Exposed to 
diisocyanates 
workers asthmatic no 
diisocyanate related 
asthma n = 9
Not exposed to 
diisocyanates non-
asthmatic no 
diisocyante related 
asthma n = 7
Gender
    Male 13 8 8 1
    Female 2 2 1 6
Age (years) (mean ± SD) 38.5 ± 9.9 36.5 ± 9.9 44.9 ± 7.5 37.9 ± 11.0
Mean (±SD) duration of exposure to 
diisocyanates (months)
66.8 ± 83.0 60.5 ± 54.3 152.5 ± 109.3 Not applicable
Last exposure to diisocyanates prior 
to sample collection (mean days ± 
SD)
94.8 ± 136.9 140.9 ± 113.1 170.9 ± 256.1 Not applicable
Challenge test positive to MDI Yes No No No
Detect or non-detect 4 detect 4 detect 3 detect 1 detect
Sabbioni 4 NQ 1 NQ 2 NQ 0 NQ
Modified method 7 ND 5 ND 4 ND 6 ND
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